Chemomab Therapeutics Advances Nebokitug Phase 3 Trial with Regulatory Support

Tip Ranks
2025.11.21 11:44
portai
I'm PortAI, I can summarize articles.

Chemomab Therapeutics announced significant progress in its nebokitug Phase 3 trial for primary sclerosing cholangitis, receiving positive feedback from the FDA and EMA. The company presented favorable Phase 2 data and is exploring partnering options to support the Phase 3 program. Chemomab expects its cash runway to last through the end of 2026. The latest analyst rating on CMMB stock is a Buy with a $25.00 price target, though TipRanks' AI Analyst rates it as Underperform due to financial challenges.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

The latest update is out from Chemomab Therapeutics ( (CMMB) ).

Chemomab Therapeutics announced its third quarter 2025 financial results and provided a corporate update, highlighting significant progress in its nebokitug Phase 3 trial for primary sclerosing cholangitis (PSC). The company received positive feedback from both the FDA and EMA, supporting a single Phase 3 registration trial with a composite endpoint, and presented favorable Phase 2 data at the AASLD 2025 conference. Chemomab is exploring multiple partnering options to support the Phase 3 program and expects its cash runway to last through the end of 2026.

The most recent analyst rating on (CMMB) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.

Spark’s Take on CMMB Stock

According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.

Chemomab Therapeutics’ overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company’s future performance heavily relies on its ability to develop and commercialize products successfully.

To see Spark’s full report on CMMB stock, click here.

More about Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet needs.

Average Trading Volume: 179,584

Technical Sentiment Signal: Sell

Current Market Cap: $13.97M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.